Search

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

Partnering Purpose: BI Gives Back | Boehringer Ingelheim US

Hear from Sheila Denton, Senior Vice President, General Counsel and Corporate Secretary, on the importance of giving back to our communities.

A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US

Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care

Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US

Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

Protocols to Trim Mastitis in your Herd | Boehringer Ingelheim US

Read more on how the Boehringer Ingelheim mastitis grading chart protocols lead to creating better informed mastitis treatment decisions in livestock.

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Yankees Legend Bernie Williams and Celebrity Vocal Coach Eric Vetro Harness the Power of Music with Tune In To Lung Health® for Interstitial Lung Disease Awareness

An extension of Boehringer Ingelheim’s Breathless® campaign, Tune In To Lung Health explores how music and breathing may help motivate, inspire, and support people living with interstitial lung disease (ILD) Program resources introduced during September’s

Boehringer Ingelheim Office Hours

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Venture Fund

AI-Driven Model Validated to Predict Risk of CKD Progression

Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Boehringer Ingelheim Subsidiaries and Affiliate Companies

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Medicines reach record number of people, net sales rise

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers